AOA Dx

TBT! Our co-founder and CRO Anna Milik Jeter spoke at the Utah Life Science Summit and was part of a fire-side chat with Liz Powell, President+ Founder of G2G - Innovative Government Affairs Consulting and Angela Dotson, CEO of Empress Medical ??

Last week, we hosted a group of students and postdocs from CU Anschutz on Friday at our Denver HQ! Anna Milik Jeter, Vuna Fa and various members of the R&D team held rotational sessions with the group which focused on topics such as Start-Up Mode, Professional Journey, and Transition to Industry! Thank you to everyone who participated and who made this such a memorable day.

We are honored to be named the Rising Star at the 21st Annual Colorado BioScience Association Awards, presented by AGC Biologics! Thank you to our Chief Science Officer Abigail McElhinny for representing AOA Dx. Colorado has been an incredible place to grow our team and thrive within a community of pioneering biotech innovators!

We’re excited to officially introduce the AOA Dx Symptomatic Campaign: Changing the Narrative on Ovarian Cancer??? For too long, ovarian cancer has been mischaracterized as a “silent killer”, known as a disease with little to no warning signs. But this isn’t the full story. ?? New research shows that *ovarian cancer is symptomatic*! Many women report symptoms like bloating, pelvic pain, and frequent urination months, before diagnosis. Unfortunately, these early signs are often misinterpreted or dismissed. At AOA Dx, we’re on a mission to not only make early detection a reality, but shift this narrative. Over the coming few months, we’ll share patient stories, insights from physicians and researchers, data-driven infographics, expert commentaries to highlight the need for better ovarian cancer diagnostics, and more! Stay tuned! ?? #ovariancancer #womenshealth

Exciting to see advancements in cancer diagnostics as researchers continue exploring ways to accelerate the path from diagnosis to treatment: https://lnkd.in/d2Faf6eb Progress in identifying biomarkers for cancers like ovarian and breast holds promise for improving patient outcomes across the board. Every step forward in this field brings us closer to earlier and more effective care! Congrats to Ludmil B. Alexandrov and his team at UC San Diego ??

"The high cost of treatment of ovarian cancer makes it likely that a shift toward early-stage detection would drive down costs, and the present effort addresses this possibility." Read the full study here: https://lnkd.in/dV8tVWH7

Had an incredible day with the AOA Dx team in beautiful Arvada, CO! Bringing the team together outside the office allowed us to connect, collaborate, and grow in new ways. From team-building exercises and hands-on pitch practice to a fantastic evening of cooking together, it was all about embracing the startup mentality and pushing each other forward. We shared insights on the resilience and agility it takes to drive innovation, especially in the biotech space, and discussed how we can apply these lessons to our mission at AOA Dx. This one-day offsite gave us a fresh perspective and renewed energy as we work towards groundbreaking early cancer detection solutions. Cheers to an inspiring day with an incredible team! Here’s to many more moments like these as we continue our journey together. cc: Oriana Papin-Zoghbi Anna Milik Jeter Emma Martin Elizabeth Yarber Michael Matthews Abigail McElhinny Robert Law, Ph.D. Melody Lucier, MHRM, PHR Lindsey Kemp Savannah Harris Michael Delaney Moises Zapata Connor Hansen Brendan Giles Adam Cadwallader Vuna Fa Charles M. Nichols, Ph.D. Jeanne Jones Enkhtuya Radnaa Rachel C. Maria Wong

Ovarian cancer is NOT silent ???? - there ARE symptoms! Amanda’s story is just one of many we've encountered over the years. Stories like hers motivate us daily to make early detection a reality. "Because no effective screening test currently exists,?70% of people with ovarian cancer?are diagnosed at advanced stages, when?chances of cure?are poor. Around 60% to 90% of people with stage one or two cancer that stays around the ovaries and pelvis are disease-free five years after diagnosis, compared with only 10% to 40% of those with stage three or four cancer that has spread through the abdomen and beyond."

Are you going to the Annual Advancing Precision Medicine conference? Don't miss Oriana Papin-Zoghbi's panel discussion with Sarah Huah!

The belief that ovarian cancer is a 'silent killer' is outdated and has been dispelled. This editorial by Barbara A. Goff, MD, highlights that more than 70% of women with early-stage, high-grade serous ovarian cancer experience symptoms before diagnosis. At AOA Dx, we’re committed to advancing early detection and empowering women and healthcare professionals to recognize these signs sooner. Early diagnosis saves lives.